手術不能進行胃癌に対する化学療法

Although the incidence of gastric cancer is declining in Japan, it is still the second common cancer. After ２０００ year, several new anticancer drugs for gastric cancer have been developed, and overall response rate and survival have been ７‐５１％ and ６‐１２ months respectively. However, these are still unsatisfactory results and the majority of the metastatic gastric cancer is incurable. We proposed a triplet regimen consisting of docetaxel, cisplatin and S‐１（DCS）, and performed phase I and II study. The results showed that response rate was８７．１％ and overall survival was ２２ months. Now, phase III study is under way. In addition, recently efficacy of herceptin, an antibody agent against HER２, was proved for HER２ positive gastric cancer. This is the first molecular targeting drug that was approved for gastric cancer. In future, combination of herceptin and cytotoxic anticancer drugs such as DCS regimen will be tested.